Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

ClinicalTrials.gov ID: NCT07926893

Public ClinicalTrials.gov record NCT07926893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of Cosibelimab (CK-301; UNLOXCYT) in Combination With Lenalidomide in Patients With Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I trial tests the safety, side effects and best dose of lenalidomide in combination with cosibelimab for the treatment of patients with mycosis fungoides or Sézary syndrome that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory).Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Immunotherapy with monoclonal antibodies, such as cosibelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide in combination with cosibelimab may be safe and tolerable in treating patients with relapsed or refractory mycosis fungoides or Sézary syndrome.

Study identification

NCT ID: NCT07926893
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: City of Hope Medical Center; Other
Enrollment: 14 participants

Conditions and interventions

Conditions

Interventions

Procedure · Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 16, 2027 (Estimated)
Primary completion: May 16, 2028 (Estimated)
Completion: May 16, 2028 (Estimated)
Last update posted: Nov 9, 2026

2027 – 2028

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
City of Hope Medical Center	Duarte	California	91010	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07926893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 9, 2026 · Synced Nov 10, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07926893 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →